nach oben

Erschienen in:

01.09.2010

Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters

verfasst von: M. M. Blokhuis, G. E. Pietersen, P. A. Goldberg, U. Algar, L. Van der Merwe, N. Mbatani, A. A. Vorster, R. S. Ramesar

Erschienen in: Familial Cancer | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Lynch Syndrome (LS) is a cancer susceptibility syndrome caused mostly by mutations in the mismatch repair genes, hMLH1, hMSH2 and hMSH6. Mutation carriers are at risk of colorectal and endometrial cancer and, less frequently, cancer of the ovaries, stomach, small bowel, hepatobiliary tract, ureter, renal pelvis and brain. The influence of environmental factors on extracolonic cancer risk in LS patients has not been investigated thus far. The aim of this study was to investigate some of these factors in South African females carrying the hMLH1 c.C1528T mutation and their mutation-negative relatives. Data were collected from 87 mutation-positive females and 121 mutation-negative female relatives regarding age, cancer history, hormonal contraceptive use, parity, duration of breast feeding, height, weight and age at first birth, last birth, menarche and menopause. Influence of these factors on cancer risk was analysed by mixed-effects generalised linear models. Extracolonic cancer occurred in 14% (12/87) of mutation-positive females versus 7% (8/121) of mutation-negative females, (P = 0.0279, adjusted for age and relatedness between women). Breast cancer was the most common extracolonic cancer. An association was found for oral contraceptive use and extracolonic cancer risk in mutation-negative females only. No association was found for any of the other risk factors investigated, when adjusted for age. This might be due to the scarcity of extracolonic cancers in our data. Future knowledge on the influence of additional environmental factors on cancer risk in LS females can lead to evidence-based lifestyle advice for mutation carriers, thereby complementing the prevention strategies available today. In addition, it can contribute to an integrated model of cancer aetiology. Therefore, this study should be taken as a thrust for further research.

Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218CrossRefPubMed

Amant F, Moerman P, Neven P et al (2005) Endometrial cancer. Lancet 366:491–505CrossRefPubMed

Blokhuis MM, Goldberg PA, Pietersen GE et al (2008) The extracolonic cancer spectrum in females with the ‘South African’ hMLH1 c.C1528T mutation. Fam Cancer 7:191–198CrossRefPubMed

Brohet RM, Goldgar DE, Easton DF et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaboration group. J Clin Oncol 25:3831–3836CrossRefPubMed

Burn J, Bishop T, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578CrossRefPubMed

Burn J, Mathers JC, Gerdes AM, et al. (2009) Cancer occurrence during follow-up of the CAPP2 study—aspirin use for up to 4 years significantly reduces Lynch syndrome cancers for up to 10 years. [cited 2009 Sept 07]. Available from: URL: http://www.capp2.com/newsZone/readnews.php?NewsID=45

Chang-Claude J, Andrie N, Rookus M et al (2007) Age at menarche and menopause and breast cancer risk in the international BRCA1/2 carrier cohort study. Cancer Epidemiol Biomarkers Prev 16:740–746CrossRefPubMed

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 371:303–314CrossRefPubMed

Cook LS, Weiss NS, Doherty JA (2006) Endometrial cancer. In: Schottenfeld D, Fraumeni JF et al (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 1027–1043

10.

Diergaarde B, Braam H, Vasen HF et al (2007) Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 5:736–742CrossRefPubMed

11.

Dove-Edwin I, Boks D, Goff S et al (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94:1708–1712CrossRefPubMed

12.

Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110CrossRefPubMed

13.

Felix R, Bodmer W, Fearnhead NS et al (2006) GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res 602:175–181PubMed

14.

Goecke T, Schulmann K, Engel C et al (2006) Genotype–phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 24:4285–4292CrossRefPubMed

15.

Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology; the lifelong interplay of genes, lifestyle and hormones. Breast Cancer Res 6:213–218CrossRefPubMed

16.

Jäger AC, Bisgaard ML, Myrhoj T et al (1997) Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 61:129–138CrossRefPubMed

17.

Järvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834CrossRefPubMed

18.

Lin KM, Shashidharan M, Ternent CA et al (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum 41:428–433CrossRefPubMed

19.

Lynch PM (2007) Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC. Digestion 76:68–76CrossRefPubMed

20.

McLaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34CrossRefPubMed

21.

Mokbel K (2003) Risk-reducing strategies for breast cancer-a review of recent literature. Int J Fertil Womens Med. 48:274–277PubMed

22.

Narod SA, Risch H, Moslehi R et al (1998) Oral contraceptives and the risk of hereditary ovarian cancer: Hereditary Ovarian Clinical Study Group. N Engl J Med 339:424–428CrossRefPubMed

23.

Parc Y, Boisson C, Thomas G et al (2003) Cancer risk in 348 French MSH2 or MLH1 gene carriers. J Med Genet 40:208–213CrossRefPubMed

24.

Peltomaki P, Gao X, Mecklin JP (2001) Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different versus shared predisposing mutations. Fam Cancer 1:9–15CrossRefPubMed

25.

Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42:491–496CrossRefPubMed

26.

Ramesar RS, Madden MV, Felix R et al (2000) Molecular genetics improves the management of hereditary non-polyposis colorectal cancer. S Afr Med J 90:709–714PubMed

27.

Renkonen-Sinisalo L, Butzow R, Leminen A et al (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120:821–824CrossRefPubMed

28.

Rijcken FE, Mourits MJ, Kleibeuker JH et al (2003) Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 91:74–80CrossRefPubMed

29.

Smith A, Moran A, Boyd MC et al (2007) Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet 44:10–15CrossRefPubMed

30.

Stupart DA, Goldberg PA, Algar U, Ramesar RS (2009) Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation. Fam Cancer 8:519–523CrossRefPubMed

31.

Stupart DA, Goldberg PA, Algar U, Ramesar RS (2009) Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 11:126–130CrossRefPubMed

32.

Vasen HFA, Möslein G, Alonso A et al (2007) Guidelines for the clinical managment of Lynch syndrome (hereditaity non-polyposis cancer. J Med Genet 44:353–362CrossRefPubMed

33.

Vasen HFA, Stormorken A, Menko FH et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080PubMed

34.

Vasen HF, Wijnen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027CrossRefPubMed

35.

Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456CrossRefPubMed

36.

Voskuil DW, Kampman E, Grubben MJ et al (2002) Meat consumption and meat preparation in relation to colorectal adenomas among sporadic and HNPCC family patients in The Netherlands. Eur J Cancer 38:2300–2308CrossRefPubMed

37.

Watson P, Ashwathnarayan R, Lynch HT et al (2004) Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Arch Intern Med 164:2429–2431CrossRefPubMed

38.

Watson P, Riley B (2005) The tumor spectrum in the Lynch syndrome. Fam Cancer 4:245–248CrossRefPubMed

39.

No authors listed (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347:1713–27

Titel: Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters
verfasst von: M. M. Blokhuis
G. E. Pietersen
P. A. Goldberg
U. Algar
L. Van der Merwe
N. Mbatani
A. A. Vorster
R. S. Ramesar
Publikationsdatum: 01.09.2010
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 3/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9334-9

Springer Medizin

Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c.C1528T mutation carriers and their mutation-negative sisters

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Familial adenomatous polyposis (FAP) and gender. Does gender influence the genetic transmission of FAP?

Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland

Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families

Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer

Can self-esteem, mastery and perceived stigma predict long-term adjustment in women carrying a BRCA1/2-mutation? Evidence from a multi-center study

Survey of familial glioma and role of germline p16 INK4A /p14 ARF and p53 mutation

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie